Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MC4R | P32245 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6379160 | 0.98 | KEAP1 (0.47) | KEAP1ADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL5795776 | 0.86 | KEAP1 (0.55) | KEAP1ADRA2CHIF1ANPC1ALDH1A1 | |
| SCHEMBL5795484 | 0.86 | KEAP1 (0.55) | KEAP1ADRA2CHIF1ANPC1ALDH1A1 | |
| SCHEMBL515194 | 0.86 | L3MBTL1 (0.45) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| Hydrochloric Acid SCHEMBL10677507 | 0.84 | KEAP1 (0.53) | KEAP1LMNAHIF1AKDM4ENPC1 | |
| SCHEMBL7900203 | 0.81 | GAA (0.49) | KEAP1HIF1ANPC1ALDH1A1GAA | |
| SCHEMBL4547918 | 0.78 | GAA (0.48) | KEAP1NPC1ALDH1A1GAAKCNQ2 | |
| Hydrochloric Acid SCHEMBL23064470 | 0.77 | GAA (0.47) | KEAP1NPC1ALDH1A1GAAKCNQ2 | |
| SCHEMBL12190503 | 0.77 | KEAP1 (0.52) | KEAP1NPC1ALDH1A1GAAKCNQ2 | |
| SCHEMBL5792053 | 0.77 | MC4R (0.55) | KEAP1GAAKCNQ2MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548469-B1 | METHOD FOR THE MANUFACTURE OF EFAVIRENZ | UNIV NELSON MANDELA METROPOLITAN (ZA) | 2020-08-26 | — | — | EP | claimed |
| US-9073817-B2 | Efficient process to induce enantioselectivity in procarbonyl compounds | LAURUS LABS PRIVATE LIMITED (IN) | 2015-07-07 | — | — | US | claimed |
| US-20120264933-A1 | EFFICIENT PROCESS TO INDUCE ENANTIOSELECTIVITY IN PROCARBONYL COMPOUNDS | LAURUS LABS PRIVATE LIMITED (IN) | 2012-10-18 | — | — | US | claimed |
| EP-0944610-B1 | ASYMMETRIC SYNTHESIS OF BENZOXAZINONES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-02-16 | — | — | EP | claimed |
| EP-0981520-B1 | EFFICIENT ENANTIOSELECTIVE ADDITION REACTION USING AN ORGANOZINC REAGENT | MERCK & CO INC (US) | 2004-07-07 | — | — | EP | claimed |
| EP-0828703-B1 | ASYMMETRIC SYNTHESIS OF (-) 6-CHLORO-4-CYCLOPROPYL-ETHYNYL-4-TRIFLUOROMETHYL-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONE | MERCK & CO INC (US) | 2000-09-20 | — | — | EP | claimed |
| US-5932726-A | VIRICIDE, ENZYME INHIBITOR; 6-CHLORO-4-CYCLOPROPYLETHYNYL4-TRIFLUOROMETHYL-1,4-DIHYDRO2H-3 ,1-BENZOXAZIN-2-ONE | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-08-03 | — | — | US | claimed |
| US-5633405-A | REACTING SUBSTITUTED NOREPHEDRINE WITH CYCLOPROPYLACETYLENE AND LITHIATING AGENT IN APROTIC SOLVENT, MIXING WITH ANILINE TRIFLUOROMETHYL KETONE, QUENCHING WITH PROTON SOURCE | MERCK & CO., INC. (US) | 1997-05-27 | — | — | US | claimed |
| EP-3548469-B1 | METHOD FOR THE MANUFACTURE OF EFAVIRENZ | UNIV NELSON MANDELA METROPOLITAN (ZA) | 2020-08-26 | — | — | EP | disclosed |
| CN-111548317-A | Efavirenz synthesis method and method for preparing intermediate thereof | 苏州纪元康生物科技有限公司 | 2020-08-18 | — | — | CN | disclosed |
| US-10689353-B2 | Method for the manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-06-23 | — | — | US | disclosed |
| US-20200062722-A1 | Method For The Manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-02-27 | — | — | US | disclosed |
| US-9676735-B2 | Process for the preparation of efavirenz and devices suitable therefore | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-03-02 | — | — | US | disclosed |
| US-5925789-A | MULTISTAGE PROCESS WITH AMINATION, DEHYDRATION AND STIRRING TO GIVE AN INTERMEDIATE IN THE SYNTHESIS OF 6-CHLORO-4-CYCLO PROPYLETHYNYL-4-TRIFLUOROMETHYL-1,4-2H-3,1-BENZOXAZINE-2-ONE AS AN INHIBITOR OF HIV REVERSE TRANSCRIPTASE | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-07-20 | — | — | US | disclosed |
| US-5856492-A | N-HYDROXYHYDROCARBYL-N-HETEROCYCLE, REVERSE TRANSCRIPTASE INHIBITOR INTERMEDIATE | MERCK & CO., INC. (US) | 1999-01-05 | — | — | US | disclosed |
| WO-1998045278-A1 | ASYMMETRIC SYNTHESIS OF BENZOXAZINONES VIA NEW INTERMEDIATES | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998027073-A1 | ASYMMETRIC SYNTHESIS OF BENZOXAZINONES | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| US-5698741-A | HIV REVERSE TRANSCRIPTASE INHIBITOR | MERCK & CO. INC. (US) | 1997-12-16 | — | — | US | disclosed |
| US-5633405-A | REACTING SUBSTITUTED NOREPHEDRINE WITH CYCLOPROPYLACETYLENE AND LITHIATING AGENT IN APROTIC SOLVENT, MIXING WITH ANILINE TRIFLUOROMETHYL KETONE, QUENCHING WITH PROTON SOURCE | MERCK & CO., INC. (US) | 1997-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | CYP3A4, CYP2C19, CYP3A43 | KEAP1 2518/4885ADRA2A 3003/4885ADRA2C 2334/4885 |
| US-20120264933-A1 | EFFICIENT PROCESS TO INDUCE ENANTIOSELECTIVITY IN PROCARBONYL COMPOUNDS | OTC, MCCC2, SLC6A5 | KEAP1 849/4885ADRA2A 3139/4885ADRA2C 2746/4885 |
| US-10689353-B2 | Method for the manufacture of Efavirenz | CYP2F1, CYP2D6, CYP3A4 | KEAP1 2244/4885ADRA2A 733/4885ADRA2C 623/4885 |
| US-20200062722-A1 | Method For The Manufacture of Efavirenz | CYP2F1, CYP2D6, CYP3A4 | KEAP1 2244/4885ADRA2A 733/4885ADRA2C 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.